Spark Therapeutics' Vision Loss Gene Therapy Heads For EU Market

A gene therapy for inherited retinal conditions leading to blindness could be marketed in Europe in 2018, but needs to avoid the setbacks dealt to UniQure’s gene therapy, Glybera, that is being withdrawn from the EU market.